We are a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments. We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. Our antivirals target the replication process and are designed to be safe, broad-spectrum, resistant and convenient to administer.

We are quickly and efficiently advancing multiple programs with clinical development underway for influenza, norovirus and coronaviruses, while also discovering and developing antiviral compounds for other high-value indications.

Preclinical Hepatitis C Programs

CC-2859

CC-2850 is a novel pan-genotypic nucleoside prodrug with similar HCV potency and cytotoxicity profile as sofosbuvir and delivers higher levels of the active metabolite (nucleoside 5'-triphosphate) compared to sofosbuvir.

CC-2069

CC-2069 is a novel highly potent, pan-genotypic, NS5A inhibitor that produces an active metabolite (also a pM HCV inhibitor).

Preclinical Hepatitis C Programs

Sign Up for Email Alerts